SCHEMBL15020745

SCHEMBL15020745

Cc1nn2c(-c3ccc(F)cc3)cc(N3CCCC3CO)nc2c1I

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 4/20 0.48
SCN9A Q15858 4/20 0.48
ADORA2A P29274 1/20 0.40
ADORA1 P30542 1/20 0.40
EGLN2 Q96KS0 2/20 0.38
BCL6 P41182 1/20 0.38
TACR1 P25103 1/20 0.36
TACR3 P29371 1/20 0.36
ITGB2 P05107 1/20 0.36
ICAM1 P05362 1/20 0.36
ITGAL P20701 1/20 0.36
APOL1 O14791 1/20 0.35
KDM4E B2RXH2 1/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
HSD17B10 Q99714 1/20 0.35
NTRK1 P04629 1/20 0.35
SYK P43405 1/20 0.35
SRC P12931 2/20 0.34
ENPP2 Q13822 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10071863 1.00 FPR2 (0.48) FPR2SCN9AADORA2AADORA1EGLN2
SCHEMBL15020616 0.91 FPR2 (0.41) FPR2SCN9AADORA2AADORA1EGLN2
SCHEMBL257313 0.91 FPR2 (0.41) FPR2SCN9AADORA2AADORA1EGLN2
SCHEMBL10072121 0.91 FPR2 (0.41) FPR2SCN9AADORA2AADORA1EGLN2
SCHEMBL15020911 0.91 FPR2 (0.41) FPR2SCN9AADORA2AADORA1EGLN2
SCHEMBL257208 0.87 FPR2 (0.45) FPR2SCN9AADORA2AADORA1EGLN2
SCHEMBL15020613 0.87 FPR2 (0.45) FPR2SCN9AADORA2AADORA1EGLN2
SCHEMBL15042187 0.86 MAPT (0.47) FPR2SCN9ABCL6KDM4ETP53
SCHEMBL15020900 0.86 KDM4E (0.42) FPR2SCN9AADORA2AADORA1EGLN2
SCHEMBL257323 0.86 KDM4E (0.42) FPR2SCN9AADORA2AADORA1EGLN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 EP disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 FPR2 2908/4885SCN9A 615/4885ADORA2A 1193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.